Abstract
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).
© 2015 American Society for Clinical Pharmacology and Therapeutics.
Publication types
-
Practice Guideline
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Biotransformation
-
Cytochrome P-450 CYP2C19 / genetics*
-
Cytochrome P-450 CYP2C19 / metabolism
-
Cytochrome P-450 CYP2D6 / genetics*
-
Cytochrome P-450 CYP2D6 / metabolism
-
Drug Dosage Calculations*
-
Genotype
-
Humans
-
Patient Safety
-
Pharmacogenetics / standards*
-
Phenotype
-
Polymorphism, Genetic*
-
Risk Assessment
-
Risk Factors
-
Selective Serotonin Reuptake Inhibitors / administration & dosage*
-
Selective Serotonin Reuptake Inhibitors / adverse effects
-
Selective Serotonin Reuptake Inhibitors / pharmacokinetics
Substances
-
Serotonin Uptake Inhibitors
-
CYP2C19 protein, human
-
Cytochrome P-450 CYP2C19
-
Cytochrome P-450 CYP2D6